Abstract:Abstract Objective: The aim of this study is to screen and identify novel leading compounds 5 which can inhibit protein Janus Kinase 3 (JAK3) from a drug library (ZINC database) 6 to provide precise target therapy for lung cancer. 7Methods: A set of computation-aided structural biology methods and chemical virtual 8 screening techniques were carried out to screen novel inhibitor compounds. Libdock 9 scores for potential inhibitors of JAK3 were calculated using fast docking method-10 virtual screening. Next, ADMET properties (absorption, distribution, metabolism, 11 excretion, and toxicity) were conducted to predict their pharmacological characteristics. 12 The binding affinity as well as the interactions between the candidate compounds and 13 JAK3 were calculated and visualized by precise molecular docking algorithm. 14 Ultimately, molecular dynamics simulation (MD) was performed to estimate the 15 stability of the ligand-JAK3 complex under natural environment. 16Results: After screening, two novel natural compounds, ZINC000014952116 and 17 ZINC00000393864, were finally selected as leading compounds from the ZINC15 18 database, which possessed less Ames mutagenicity, rodent carcinogenicity and 19 developmental toxicity potential than other candidate compounds. Additionally, they 20 didn’t inhibit the activity of CYP2D6. Molecular dynamics simulation analysis showed 21 that ZINC000014952116 and ZINC00000393864 could interact with JAK3 steadily, 22 and their ligand-JAK3 complexes could keep stable under natural situation, and act as 23 regulatory role to JAK3. 24Conclusion: This study analyzed that ZINC000014952116 and ZINC00000393864 25 were ideal natural inhibitors targeting JAK3 from the ZINC15 database, which could 26 also provide more options and resources for other cancer chemotherapy.

Rational Modification, Synthesis and Biological Evaluation of 3,4-Dihydroquinoxalin-2(1h)-one Derivatives As Potent and Selective C-Jun N-terminal Kinase 3 (JNK3) Inhibitors.

The Structure-Based Optimization of 3-Substituted Indolin-2-one Derivatives As Potent and Isoform-Selective C-Jun N-terminal Kinase 3 (JNK3) Inhibitors and Biological Evaluation.

Identifying New Ligands for JNK3 by Fluorescence Thermal Shift Assays and Native Mass Spectrometry

Identify of promising isoquinolone JNK1 inhibitors by combined application of 3D-QSAR, molecular docking and molecular dynamics simulation approaches

Design and Synthesis of Highly Potent and Isoform Selective Jnk3 Inhibitors: Sar Studies on Aminopyrazole Derivatives

Structural Requirements of Isoquinolones As Novel Selective C-Jun N-terminal Kinase 1 Inhibitors: 2D and 3D QSAR Analyses.

Pyridopyrimidinone Derivatives As Potent And Selective C-Jun N-Terminal Kinase (Jnk) Inhibitors

Design, synthesis and biological evaluation of novel O-substituted tryptanthrin oxime derivatives as c-Jun N-terminal kinase inhibitors

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

Design, Synthesis, and Pharmacological Evaluation of 4- or 6-Phenyl-pyrimidine Derivatives As Novel and Selective Janus Kinase 3 Inhibitors.

Selective Covalent Inhibiting JNK3 by Small Molecules for Parkinson's Diseases

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors

Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors.

Insights into the c-Jun N-terminal kinase 3 (JNK3) inhibitors: CoMFA, CoMSIA analyses and molecular docking studies

Discovery of Novel Indazole Chemotypes As Isoform-Selective JNK3 Inhibitors for the Treatment of Parkinson's Disease

Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitors

Development of a Covalent Inhibitor of C-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1.

Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives As Novel and Isoform-Selective C-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases.

Computational Study on Novel Natural Inhibitors Targeting Janus Kinase 3

Structural Basis and Biological Consequences for JNK2/3 Isoform Selective Aminopyrazoles